Armin Nazemi Zadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Armin Nazemi Zadeh has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Mahdi Hesaraki
Department of Animal Sciences and Marine Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran
2 shared publications - Benyamin Mashhadi
Department of Photodynamic, Medical Laser Research Center, Yara Institute, ACECR, Tehran, Iran
1 shared publication Farshid Yekani
Medical Genetics and Biotechnology Research Hub, Royan TuCAGene Ltd., Tehran, Iran
1 shared publication- Fatemeh Haghdoost
Department of Regenerative Medicine in Wound Healing, Medical Laser Research Center, Yara Institute Academic Center for Education, Culture and Research (ACECR), Tehran, Iran
1 shared publication - Fatemeh Hosseini Ghaemi
Department of Developmental Biology, School of Basic Sciences and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran
1 shared publication - Fatemeh Karami-Tehrani
Department of Clinical Biochemistry, Cancer Research Laboratory, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 1 August 2026
- Published by InkVista Publishing House
- Vol. 19 (1) , 49-63
The expression of HGPRTase in the malignant and benign breast tumors: The correlation with clinicopathological status
Introduction: Breast cancer is the most common malignancy among women worldwide. Although several biomarkers, such as ER, PR, HER-2, and Ki-67, are routinely used for diagnosis and prognosis, there remains a need for additional markers that can reliably distinguish malignant from benign lesions. Hypoxanthine-guanine phosphoribosyl transferase 1 (HPRT1), a key enzyme in the ...
- 1 August 2026
- Published by InkVista Publishing House
- Vol. 19 (1) , 49-63
Open AccessThe expression of HGPRTase in the malignant and benign breast tumors: The correlation with clinicopathological status
Introduction: Breast cancer is the most common malignancy among women worldwide. Although several biomarkers, such as ER, PR, HER-2, and Ki-67, are routinely used for diagnosis and prognosis, there remains a need for additional markers that can reliably distinguish malignant from benign lesions. Hypoxanthine-guanine phosphoribosyl transferase 1 (HPRT1), a key enzyme in the ...
- Open Access
- 30 July 2026
- Published by Maad Rayan Publishing Company in Biomedicine Advances
- Vol. 3 (3) , 92-104
Harnessing Regenerative Medicine to Improve Wound Healing Outcomes: Cellular Therapies, Biomaterials, and Nanomedicine
Regenerative medicine examines how to use stem cells, growth factors, cellular dressings, skin substitutes, biopolymers, hydrogels, exosome-based systems, and nanoparticle-enabled delivery platforms to improve Wound Healing. It is increasingly shaping the therapeutic and conceptual approach to wound care by shifting the goal of treatment from simple wound closure to the restoration of functional tissue. This review discusses the biological rationale of wound healing. The normal process of wound healing includes several coordinated and overlapping phases of hemostasis, inflammation, proliferation, and remodeling. This sequence often is disrupted in burns, diabetic ulcers, infected wounds, and extensive traumatic injuries, which leads to chronic inflammation, delayed vascularization, defective extracellular matrix deposition, or poor epithelial regeneration. Regenerative strategies, by providing instructive cells, paracrine signals, structural scaffolds, or controlled local delivery of bioactive molecules, try to correct these failures. Regenerative medicine has seen significant advances with the development of living skin substitutes, growth factor-loaded matrices, dynamic hydrogels, electrospun nanofibers, bioprintable bioinks, and smart wound dressings. However, the variability of biomaterial composition, poor regeneration of vascular and appendages, manufacturing complexity, cost, safety concerns, and the need for standardized potency assays still limit clinical translation. A more integrated approach that combines biological signaling, scaffold design, antimicrobial control, and patient-specific wound assessment may help bridge the gap between promising experimental systems and clinically reliable regenerative wound therapies.
- 30 July 2026
- Published by Maad Rayan Publishing Company in Biomedicine Advances
- Vol. 3 (3) , 92-104
Open AccessHarnessing Regenerative Medicine to Improve Wound Healing Outcomes: Cellular Therapies, Biomaterials, and Nanomedicine
Regenerative medicine examines how to use stem cells, growth factors, cellular dressings, skin substitutes, biopolymers, hydrogels, exosome-based systems, and nanoparticle-enabled delivery platforms to improve Wound Healing. It is increasingly shaping the therapeutic and conceptual approach to wound care by shifting the goal of treatment from simple wound closure to the restoration of functional tissue. This review discusses the biological rationale of wound healing. The normal process of wound healing includes several coordinated and overlapping phases of hemostasis, inflammation, proliferation, and remodeling. This sequence often is disrupted in burns, diabetic ulcers, infected wounds, and extensive traumatic injuries, which leads to chronic inflammation, delayed vascularization, defective extracellular matrix deposition, or poor epithelial regeneration. Regenerative strategies, by providing instructive cells, paracrine signals, structural scaffolds, or controlled local delivery of bioactive molecules, try to correct these failures. Regenerative medicine has seen significant advances with the development of living skin substitutes, growth factor-loaded matrices, dynamic hydrogels, electrospun nanofibers, bioprintable bioinks, and smart wound dressings. However, the variability of biomaterial composition, poor regeneration of vascular and appendages, manufacturing complexity, cost, safety concerns, and the need for standardized potency assays still limit clinical translation. A more integrated approach that combines biological signaling, scaffold design, antimicrobial control, and patient-specific wound assessment may help bridge the gap between promising experimental systems and clinically reliable regenerative wound therapies.
- 30 September 2025
- Published by Maad Rayan Publishing Company in International Journal of Basic Science in Medicine
- Vol. 10 (3) , 137-148
Advancements and Challenges in Organoid Technology: Applications in Disease Modeling, Drug Discovery, and Personalized Medicine
For centuries, there has been ongoing effort to regenerate living organs using tissues or their cells. Organoid technology involves the three-dimensional (3D) culture of various cell types, derived from tissue explants, tumors, stem cells, or other progenitor cells, which self-organize under controlled conditions to mimic the structure and function of real organs. Two-dimensional (2D) culture is the most exploited in vitro method providing advantages in terms of reproducibility, high throughput and cost- effectiveness. Even so, 2D culture generally fails to mimic a tissue or organ that possesses a defined 3D structure along with complicated intercellular communication. In fact, these cells are cultured in an environment similar to the body’s extracellular matrix. These organoids differentiate into functional cell types, acquiring the complexity of an organ’s anatomy and physiology. This innovative technology has revolutionized research and medicine, offering a powerful alternative to animal models in preclinical studies. Organoids have shown great promise in various therapeutic and research applications, although they are not without limitations. Despite these challenges, their potential and necessity in advancing biomedical research are undeniable. This review aims to explore both the applications and the challenges associated with organoid technology.
- 30 September 2025
- Published by Maad Rayan Publishing Company in International Journal of Basic Science in Medicine
- Vol. 10 (3) , 137-148
Advancements and Challenges in Organoid Technology: Applications in Disease Modeling, Drug Discovery, and Personalized Medicine
For centuries, there has been ongoing effort to regenerate living organs using tissues or their cells. Organoid technology involves the three-dimensional (3D) culture of various cell types, derived from tissue explants, tumors, stem cells, or other progenitor cells, which self-organize under controlled conditions to mimic the structure and function of real organs. Two-dimensional (2D) culture is the most exploited in vitro method providing advantages in terms of reproducibility, high throughput and cost- effectiveness. Even so, 2D culture generally fails to mimic a tissue or organ that possesses a defined 3D structure along with complicated intercellular communication. In fact, these cells are cultured in an environment similar to the body’s extracellular matrix. These organoids differentiate into functional cell types, acquiring the complexity of an organ’s anatomy and physiology. This innovative technology has revolutionized research and medicine, offering a powerful alternative to animal models in preclinical studies. Organoids have shown great promise in various therapeutic and research applications, although they are not without limitations. Despite these challenges, their potential and necessity in advancing biomedical research are undeniable. This review aims to explore both the applications and the challenges associated with organoid technology.